• 文献检索
  • 文档翻译
  • 深度研究
  • 学术资讯
  • Suppr Zotero 插件Zotero 插件
  • 邀请有礼
  • 套餐&价格
  • 历史记录
应用&插件
Suppr Zotero 插件Zotero 插件浏览器插件Mac 客户端Windows 客户端微信小程序
定价
高级版会员购买积分包购买API积分包
服务
文献检索文档翻译深度研究API 文档MCP 服务
关于我们
关于 Suppr公司介绍联系我们用户协议隐私条款
关注我们

Suppr 超能文献

核心技术专利:CN118964589B侵权必究
粤ICP备2023148730 号-1Suppr @ 2026

文献检索

告别复杂PubMed语法,用中文像聊天一样搜索,搜遍4000万医学文献。AI智能推荐,让科研检索更轻松。

立即免费搜索

文件翻译

保留排版,准确专业,支持PDF/Word/PPT等文件格式,支持 12+语言互译。

免费翻译文档

深度研究

AI帮你快速写综述,25分钟生成高质量综述,智能提取关键信息,辅助科研写作。

立即免费体验

载有α-突触核蛋白RNA干扰质粒的多功能磁性纳米颗粒对帕金森病模型的抑制作用

Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model.

作者信息

Niu Shuiqin, Zhang Ling-Kun, Zhang Li, Zhuang Siyi, Zhan Xiuyu, Chen Wu-Ya, Du Shiwei, Yin Liang, You Rong, Li Chu-Hua, Guan Yan-Qing

机构信息

School of Life Science, South China Normal University, Guangzhou 510631, China.; MOE Key Laboratory of Laser Life Science & Institute of Laser Life Science, College of Biophotonics, South China Normal University, Guangzhou, 510631, China.

School of Life Science, South China Normal University, Guangzhou 510631, China.

出版信息

Theranostics. 2017 Jan 1;7(2):344-356. doi: 10.7150/thno.16562. eCollection 2017.

DOI:10.7150/thno.16562
PMID:28042339
原文链接:https://pmc.ncbi.nlm.nih.gov/articles/PMC5197069/
Abstract

Lewy bodies are considered as the main pathological characteristics of Parkinson's disease (PD). The major component of Lewy bodies is α-synuclein (α-syn). The use of gene therapy that targeting and effectively interfere with the expression of α-syn in neurons has received tremendous attention. In this study, we used magnetic FeO nanoparticles coated with oleic acid molecules as a nano-carrier. -isopropylacrylamide derivative (NIPAm-AA) was photo-immobilized onto the oleic acid molecules, and shRNA (short hairpin RNA) was absorbed. The same method was used to absorb nerve growth factor (NGF) to NIPAm-AA to specifically promote neuronal uptake via NGF receptor-mediated endocytosis. Additionally, shRNA plasmid could be released into neurons because of the temperature and pH sensitivity of NIPAm-AA interference with α-syn synthesis. We investigated apoptosis in neurons with abrogated α-syn expression and . The results demonstrated that multifunctional superparamagnetic nanoparticles carrying shRNA for α-syn could provide effective repair in a PD model.

摘要

路易小体被认为是帕金森病(PD)的主要病理特征。路易小体的主要成分是α-突触核蛋白(α-syn)。靶向并有效干扰神经元中α-syn表达的基因治疗受到了极大关注。在本研究中,我们使用涂有油酸分子的磁性FeO纳米颗粒作为纳米载体。N-异丙基丙烯酰胺衍生物(NIPAm-AA)被光固定在油酸分子上,并吸附短发夹RNA(shRNA)。采用相同方法将神经生长因子(NGF)吸附到NIPAm-AA上,以通过NGF受体介导的内吞作用特异性促进神经元摄取。此外,由于NIPAm-AA干扰α-syn合成的温度和pH敏感性,shRNA质粒可释放到神经元中。我们研究了α-syn表达缺失的神经元中的细胞凋亡情况。结果表明,携带针对α-syn的shRNA的多功能超顺磁性纳米颗粒可在PD模型中提供有效的修复作用。

https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/f3e3541d55dc/thnov07p0344g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/ec88b0298bf1/thnov07p0344g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/41ef3a095df5/thnov07p0344g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/2854ac75aeff/thnov07p0344g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/f3e3541d55dc/thnov07p0344g004.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/ec88b0298bf1/thnov07p0344g001.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/41ef3a095df5/thnov07p0344g002.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/2854ac75aeff/thnov07p0344g003.jpg
https://cdn.ncbi.nlm.nih.gov/pmc/blobs/36bd/5197069/f3e3541d55dc/thnov07p0344g004.jpg

相似文献

1
Inhibition by Multifunctional Magnetic Nanoparticles Loaded with Alpha-Synuclein RNAi Plasmid in a Parkinson's Disease Model.载有α-突触核蛋白RNA干扰质粒的多功能磁性纳米颗粒对帕金森病模型的抑制作用
Theranostics. 2017 Jan 1;7(2):344-356. doi: 10.7150/thno.16562. eCollection 2017.
2
Systemic Exosomal Delivery of shRNA Minicircles Prevents Parkinsonian Pathology.系统递送 shRNA 微环可预防帕金森病病理。
Mol Ther. 2019 Dec 4;27(12):2111-2122. doi: 10.1016/j.ymthe.2019.08.010. Epub 2019 Aug 27.
3
Targeting of the class II transactivator attenuates inflammation and neurodegeneration in an alpha-synuclein model of Parkinson's disease.靶向 II 类转录激活因子可减轻帕金森病 α-突触核蛋白模型中的炎症和神经退行性变。
J Neuroinflammation. 2018 Aug 30;15(1):244. doi: 10.1186/s12974-018-1286-2.
4
Synthesis of Double Interfering Biodegradable Nano-MgO Micelle Composites and Their Effect on Parkinson's Disease.双干扰可生物降解纳米氧化镁胶束复合材料的合成及其对帕金森病的影响。
ACS Biomater Sci Eng. 2021 Mar 8;7(3):1216-1229. doi: 10.1021/acsbiomaterials.0c01474. Epub 2021 Feb 9.
5
Intracerebral Administration of a Ligand-ASO Conjugate Selectively Reduces α-Synuclein Accumulation in Monoamine Neurons of Double Mutant Human A30P*A53T*α-Synuclein Transgenic Mice.脑内给予配体-ASO 缀合物可选择性降低双突变人 A30P*A53T*α-突触核蛋白转基因小鼠单胺能神经元中 α-突触核蛋白的积累。
Int J Mol Sci. 2021 Mar 13;22(6):2939. doi: 10.3390/ijms22062939.
6
Inhibition of FK506 binding proteins reduces alpha-synuclein aggregation and Parkinson's disease-like pathology.抑制 FK506 结合蛋白可减少α-突触核蛋白聚集和帕金森病样病变。
J Neurosci. 2010 Feb 17;30(7):2454-63. doi: 10.1523/JNEUROSCI.5983-09.2010.
7
Exosome-mediated delivery of antisense oligonucleotides targeting α-synuclein ameliorates the pathology in a mouse model of Parkinson's disease.外泌体介导的靶向α-突触核蛋白的反义寡核苷酸递送至改善帕金森病小鼠模型的病理学。
Neurobiol Dis. 2021 Jan;148:105218. doi: 10.1016/j.nbd.2020.105218. Epub 2020 Dec 6.
8
Systemic peptide mediated delivery of an siRNA targeting α-syn in the CNS ameliorates the neurodegenerative process in a transgenic model of Lewy body disease.系统肽介导的靶向中枢神经系统α-突触核蛋白的 siRNA 递呈可改善路易体病转基因模型中的神经退行性过程。
Neurobiol Dis. 2019 Jul;127:163-177. doi: 10.1016/j.nbd.2019.03.001. Epub 2019 Mar 5.
9
shRNA targeting α-synuclein prevents neurodegeneration in a Parkinson's disease model.靶向α-突触核蛋白的短发夹RNA可预防帕金森病模型中的神经退行性变。
J Clin Invest. 2015 Jul 1;125(7):2721-35. doi: 10.1172/JCI64502. Epub 2015 Jun 15.
10
Induction of de novo α-synuclein fibrillization in a neuronal model for Parkinson's disease.帕金森病神经元模型中从头诱导α-突触核蛋白纤维化
Proc Natl Acad Sci U S A. 2016 Feb 16;113(7):E912-21. doi: 10.1073/pnas.1512876113. Epub 2016 Feb 2.

引用本文的文献

1
R406 and its structural analogs reduce SNCA/α-synuclein levels via autophagic degradation.R406及其结构类似物通过自噬降解降低SNCA/α-突触核蛋白水平。
Autophagy. 2025 Sep;21(9):1945-1961. doi: 10.1080/15548627.2025.2483886. Epub 2025 Apr 4.
2
Inorganic Nanoparticles-based Drug Delivery Systems for Neurodegenerative Diseases Therapy.用于神经退行性疾病治疗的无机纳米颗粒药物递送系统
Curr Pharm Des. 2025;31(25):1998-2024. doi: 10.2174/0113816128352935250116064725.
3
The potential of nanoparticle-based contrast agents in the diagnosis of neurodegenerative pathologies.

本文引用的文献

1
Design of magnetic nanoparticles for hepatocellular carcinoma treatment using the control mechanisms of the cell internal nucleus and external membrane.利用细胞核内部和细胞膜外部的控制机制设计用于治疗肝细胞癌的磁性纳米颗粒。
J Mater Chem B. 2015 May 28;3(20):4191-4204. doi: 10.1039/c5tb00514k. Epub 2015 Apr 27.
2
Magnetic, fluorescent, and thermo-responsive poly(MMA-NIPAM-Tb(AA)3Phen)/Fe3O4 multifunctional nanospheres prepared by emulsifier-free emulsion polymerization.通过无皂乳液聚合制备的磁性、荧光和热响应性聚(甲基丙烯酸甲酯-聚N-异丙基丙烯酰胺-三(丙烯酸)铽菲咯啉)/四氧化三铁多功能纳米球。
J Biomater Appl. 2015 Aug;30(2):201-11. doi: 10.1177/0885328215575761. Epub 2015 Mar 12.
3
基于纳米颗粒的造影剂在神经退行性疾病诊断中的潜力。
Nanomedicine (Lond). 2025 Feb;20(3):247-249. doi: 10.1080/17435889.2024.2428588. Epub 2024 Nov 14.
4
A Comprehensive Review of Challenges in Oral Drug Delivery Systems and Recent Advancements in Innovative Design Strategies.口服给药系统中的挑战及创新设计策略的最新进展综述
Curr Pharm Des. 2025;31(5):360-376. doi: 10.2174/0113816128338560240923073357.
5
Emerging Perspectives on Prime Editor Delivery to the Brain.向大脑递送碱基编辑器的新观点
Pharmaceuticals (Basel). 2024 Jun 11;17(6):763. doi: 10.3390/ph17060763.
6
Selenium Nanoparticles as Neuroprotective Agents: Insights into Molecular Mechanisms for Parkinson's Disease Treatment.作为神经保护剂的硒纳米颗粒:对帕金森病治疗分子机制的见解
Mol Neurobiol. 2025 Jun;62(6):6655-6682. doi: 10.1007/s12035-024-04253-x. Epub 2024 Jun 5.
7
In-depth Mechanism, Challenges, and Opportunities of Delivering Therapeutics in Brain Using Intranasal Route.经鼻给药递药于脑的深入机制、挑战和机遇
AAPS PharmSciTech. 2024 May 6;25(5):96. doi: 10.1208/s12249-024-02810-0.
8
Developing hydrogels for gene therapy and tissue engineering.用于基因治疗和组织工程的水凝胶的开发。
J Nanobiotechnology. 2024 Apr 15;22(1):182. doi: 10.1186/s12951-024-02462-z.
9
How Precise are Nanomedicines in Overcoming the Blood-Brain Barrier? A Comprehensive Review of the Literature.纳米药物在克服血脑屏障方面有多精确?文献综述。
Int J Nanomedicine. 2024 Mar 8;19:2441-2467. doi: 10.2147/IJN.S442520. eCollection 2024.
10
Nanotechnology-based Nose-to-brain Delivery in Epilepsy: A NovelApproach to Diagnosis and Treatment.基于纳米技术的经鼻脑递药在癫痫中的应用:一种新的诊断和治疗方法。
Pharm Nanotechnol. 2024;12(4):314-328. doi: 10.2174/0122117385265554230919070402.
Decreased expression of organic cation transporters, Oct1 and Oct2, in brain microvessels and its implication to MPTP-induced dopaminergic toxicity in aged mice.
脑微血管中有机阳离子转运体 Oct1 和 Oct2 表达降低及其对 MPTP 诱导的老年小鼠多巴胺能毒性的影响。
J Cereb Blood Flow Metab. 2015 Jan;35(1):37-47. doi: 10.1038/jcbfm.2014.162. Epub 2014 Sep 24.
4
Gene therapy for the nervous system: challenges and new strategies.神经系统的基因治疗:挑战与新策略
Neurotherapeutics. 2014 Oct;11(4):817-39. doi: 10.1007/s13311-014-0299-5.
5
Slowing of neurodegeneration in Parkinson's disease and Huntington's disease: future therapeutic perspectives.帕金森病和亨廷顿病中神经退行性变的减缓:未来的治疗前景。
Lancet. 2014 Aug 9;384(9942):545-55. doi: 10.1016/S0140-6736(14)61010-2. Epub 2014 Jun 18.
6
Powerful inner/outer controlled multi-target magnetic nanoparticle drug carrier prepared by liquid photo-immobilization.通过液体光固定化制备的强大的内外控多靶点磁性纳米颗粒药物载体。
Sci Rep. 2014 May 21;4:4990. doi: 10.1038/srep04990.
7
Characterization of polyethylene glycol-polyethyleneimine as a vector for alpha-synuclein siRNA delivery to PC12 cells for Parkinson's disease.聚乙二醇-聚乙烯亚胺作为α-突触核蛋白小干扰RNA载体用于帕金森病PC12细胞递送的特性研究
CNS Neurosci Ther. 2014 Jan;20(1):76-85. doi: 10.1111/cns.12176. Epub 2013 Nov 27.
8
rAAV2/7 vector-mediated overexpression of alpha-synuclein in mouse substantia nigra induces protein aggregation and progressive dose-dependent neurodegeneration.rAAV2/7 载体介导的小鼠黑质中 alpha-突触核蛋白的过表达诱导蛋白聚集和进行性剂量依赖性神经退行性变。
Mol Neurodegener. 2013 Nov 25;8:44. doi: 10.1186/1750-1326-8-44.
9
Gene-based therapies in Parkinson's disease.帕金森病的基因疗法。
Neurotherapeutics. 2014 Jan;11(1):60-7. doi: 10.1007/s13311-013-0233-2.
10
GDNF, NGF and BDNF as therapeutic options for neurodegeneration.GDNF、NGF 和 BDNF 作为神经退行性疾病的治疗选择。
Pharmacol Ther. 2013 May;138(2):155-75. doi: 10.1016/j.pharmthera.2013.01.004. Epub 2013 Jan 21.